Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Standard Medicines

Drugs

Locations

Clinical Specialty

181-200 of 1,782 trials

Follicular Lymphoma: Radiotherapy with Obinutuzumab

We are studying whether adding Obinutuzumab to local radiotherapy improves outcomes for patients with early-stage Follicular Lymphoma. This trial will help us understand the effectiveness and safety of this combination treatment.

Early Stage Follicular Lymphoma3-6 monthsConfirmation phase (III)No Placebo Standard MedicinesOncology

Aggressive B-cell Non-Hodgkin Lymphoma: Odronextamab Study

We are studying how well odronextamab works compared to standard treatments for adults with previously treated aggressive B-cell non-Hodgkin lymphoma. The trial will also look at safety and how treatment affects daily life.

B-Cell Non-Hodgkin's Lymphoma1-2 yearsConfirmation phase (III)No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematologyOncology

Diffuse Large B-Cell Lymphoma: Odronextamab vs. Rituximab

We are studying how well odronextamab combined with chemotherapy works compared to rituximab with chemotherapy in patients who have not yet received treatment for diffuse large B-cell lymphoma. The trial aims to evaluate safety and effectiveness in this patient group.

Diffuse Large B-cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematologyOncology

Primary Central Nervous System Lymphoma: MTR² Treatment Study

We are studying a new combination of medications for patients with primary central nervous system lymphoma who cannot receive intensive therapies. The goal is to see if this treatment is effective and safe, and how it affects quality of life.

Primary Central Nervous Lymphoma>2 yearsEfficacy phase (II)No Placebo Standard MedicinesHematologyNeurology

Melanoma Treatment: Fianlimab and Cemiplimab Study

We are investigating whether combining fianlimab and cemiplimab is safer and more effective than cemiplimab alone for adults with resectable stage III or IV melanoma. This study aims to see how well these treatments work before surgery.

Malignant Melanoma>2 yearsEfficacy phase (II)≤5 visits Standard Medicines Cost Reimbursement Partially RemoteDermatologyOncology

Deucravacitinib for Inflammatory Skin Conditions

We are studying a new treatment for adults with inflammatory epidermal genodermatoses, including severe forms of ichthyosis and epidermolysis bullosa. The trial will evaluate how well it works and its safety over time.

Epidermolysis BullosaCongenital Ichthyosis6-12 monthsEfficacy phase (II)6-10 visits No Placebo Standard MedicinesDermatology

Kidney Stones: Furosemide Injection Study

We are investigating whether a Furosemide injection after kidney stone removal improves the chances of being stone-free and reduces the risk of infections. This study involves patients undergoing flexible ureteroscopy for kidney stones.

Kidney Stones>2 yearsConfirmation phase (III)≤5 visits No Placebo Standard Medicines Cost ReimbursementUrology

ADHD Treatment: Dexamfetamine Formulations

We are studying two types of dexamfetamine sulfate in adults with ADHD to see if they are more effective than a placebo. The trial will also evaluate the safety of these medications.

Attention Deficit Hyperactivity Disorder (ADHD)6-12 monthsConfirmation phase (III)11-15 visits Standard MedicinesNeurologyPsychiatry

Mantle-Cell Lymphoma: KTE-X19 CAR-T Cell Therapy

We are studying a new CAR-T cell therapy for patients with relapsed or refractory mantle-cell lymphoma who responded partially to ibrutinib. The trial aims to evaluate its effectiveness and safety in improving patient outcomes.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)No Placebo Standard MedicinesHematologyOncology

HPV Vaccination Timing After Stem Cell Transplant

We are comparing early versus late vaccination with Gardasil 9® in patients who have had a stem cell transplant. The goal is to see which timing produces a stronger immune response against HPV.

Recipients of Allogeneic Stem Cell TransplantationEfficacy phase (II)No Placebo Standard MedicinesHematologyInfectious DiseasesOncology

Eptinezumab for Migraines in Children and Adolescents

We are studying the long-term safety of eptinezumab in children and teens aged 6 to 17 who experience chronic or episodic migraines. This research aims to ensure the medication is safe for young patients.

Migraine6-12 monthsConfirmation phase (III)≤5 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

Partial Lipodystrophy: Metreleptin Treatment Study

We are studying the daily use of metreleptin in patients with partial lipodystrophy to see if it improves their condition and related health factors. This includes looking at liver health and insulin sensitivity over time.

Partial Lipodystrophy>2 yearsMonitoring phase (IV)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteEndocrinologyInternal Medicine

Prostate Cancer: AAA617 Treatment Study

We are studying a new drug, AAA617, for adult men with oligometastatic prostate cancer to see if it can delay disease progression compared to standard observation. This trial aims to evaluate its effects on survival and quality of life.

Oligometastatic Prostate Cancer3-6 monthsConfirmation phase (III)11-15 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

Lung Cancer Treatment: DZD9008 vs. Chemotherapy

We are studying a new medication, DZD9008, for patients with advanced non-small cell lung cancer that has a specific genetic mutation. The goal is to see if it works better than standard chemotherapy.

Advanced Non-Small Cell Lung Cancer with EGFR MutationConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementOncologyPulmonology

Severe Infections: MODIFY Trial

We are testing a new method to guide antibiotic treatment for severe infections, aiming to reduce unnecessary antibiotic use. This study will also evaluate how this approach impacts recovery and health outcomes.

Sepsis>2 yearsConfirmation phase (III)≤5 visits No Placebo Standard Medicines Partially RemoteInfectious DiseasesInternal Medicine

Atypical Hemolytic Uremic Syndrome: Long-Term Study of Iptacopan

We are evaluating the long-term safety and effects of iptacopan in individuals with atypical hemolytic uremic syndrome. This study looks at how well the treatment works in preventing complications and improving kidney health.

Atypical Hemolytic Uremic Syndrome>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteNephrology

Filgotinib for Rare Immune Diseases

We are studying how filgotinib may improve quality of life and disease activity in patients with rare conditions like Behçet's disease, idiopathic inflammatory myopathy, and IgG4-related disease.

DermatomyositisAntisynthetase SyndromeIgG4-Related Disease6-12 monthsEfficacy phase (II)No Placebo Standard MedicinesInfectious DiseasesRheumatology

Cutibacterium acnes Infections: Rifampicin Study

We are investigating whether rifampicin is safe and effective for treating prosthetic joint infections caused by Cutibacterium acnes. This study compares rifampicin with other antibiotic treatments to see which works better.

Joint Infection from Medical Devices>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteInfectious DiseasesOrthopedics and Traumatology

Metastatic Leiomyosarcoma: Lurbinectedin and Doxorubicin Study

We are investigating whether combining lurbinectedin with doxorubicin helps patients with metastatic leiomyosarcoma live longer without disease progression compared to doxorubicin alone. This study aims to improve treatment options for this rare cancer.

Metastatic Leiomyosarcoma>2 yearsConfirmation phase (III)No Placebo Standard MedicinesOncology

Atrial Fibrillation: Stopping Anticoagulants After Heart Surgery

We are studying whether patients with atrial fibrillation can safely stop anticoagulant therapy after undergoing surgical left atrial appendage closure. This trial looks at the risks of stroke and bleeding in these patients.

Atrial Fibrillation>2 yearsMonitoring phase (IV)No Placebo Standard Medicines Cost ReimbursementCardiologyInternal Medicine

Search Clinical Trials in the European Union